GO
Loading...

Merck & Co Inc

More

  • Sun Pharma licenses Merck psoriasis drug for $80M Wednesday, 17 Sep 2014 | 11:10 AM ET

    NEW YORK— Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday. The Whitehouse Station, New Jersey, company will also get royalties on sales if the drug is approved. Shares of Merck& Co. slipped 41 cents to $59.58 in morning trading.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Sept 15- Merck& Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

  • Stocks close mixed ahead of ECB, data; Apple hit Wednesday, 3 Sep 2014 | 4:09 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed mixed on Wednesday, coming off morning highs amid economic reports and central bank news.

  • *Zoetis explores international markets for product. CHICAGO, Sept 3- Zoetis Inc has received a conditional license from the U.S. Department of Agriculture for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.

  • CHICAGO, Sept 3- Zoetis Inc, the world's largest animal-health company, has received a conditional license from the U.S. Agriculture Department for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.

  • How China is chasing business to Singapore Tuesday, 2 Sep 2014 | 2:34 PM ET
    Some firms are now finding Hong Kong, left, less appealing for their Asia headquarters than Singapore, right.

    As tensions between Hong Kong and Beijing increase, multinational firms are seeing more stability in Singapore and expanding their outlook.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Early movers: TIF, AAPL, T, AGN, PFE, TIVO & more Wednesday, 27 Aug 2014 | 8:13 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    Some of the names on the move ahead of the open.

  • Your first trade for Wednesday Tuesday, 26 Aug 2014 | 6:24 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Midday movers: Ann, Best Buy Co., Exxon & more Tuesday, 26 Aug 2014 | 12:46 PM ET

    Some of Tuesday's midday movers:

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Earnings season: Here's what we’ve learned Tuesday, 26 Aug 2014 | 7:50 AM ET

    What have we learnt from the recent reporting flurry? Societe Generale has put together a list of conclusions to be drawn from this earnings season.

  • Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.

  • Midday movers: Apple, Boeing, Tesla Motors & more Monday, 25 Aug 2014 | 1:09 PM ET

    Some of Monday's midday movers:

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.